핵심요약

• Pfizer는 현재 $24.29에 거래되며, 이는 52주 범위($21.97~$28.28)의 중간 수준에 위치합니다.
• Pfizer의 선행 주가수익비율(Forward P/E)은 8배이며, 주가수익비율(Trailing P/E)은 19배입니다.
• 2026년 1분기 매출은 $14.45억 달러로 전년 대비 5.4% 증가했으며, 조정 주당순이익(EPS)은 $0.75를 기록했습니다.
• 주요 성장 동력으로 Vyndamax 특허가 2031년 6월까지 미국 독점권을 연장하여 특허 만료 우려를 해소했습니다.
• 2026년 1분기, 출시 및 인수 제품들은 운영적으로 22% 성장했으며, 이는 Padcev(+39%), Nurtec ODT(+41%), Abrysvo(+37%)의 성장을 통해 달성되었습니다.

도입

본 기사는 시장 변동성이 커질 때 어떻게 저평가된 주식에서 기회를 찾을 수 있는지 제시하며, 단순히 주가 수준만이 아니라 예측 가능한 현금 흐름, 방어적인 베타, 그리고 배당 수익률이 투자 결정에 중요한 요소임을 강조합니다. 투자자들은 단기적인 가격 변동에 집중하기보다 내재된 펀더멘털과 장기적인 경쟁 우위를 분석해야 합니다.

본문 1: 펀더멘털과 가치 평가

Pfizer의 가치는 강력한 펀더멘털에 기반하고 있습니다. 현재 주가는 $24.29로 $45 미만이라는 낮은 밸류에이션을 보이지만, 이는 과거의 실적과 미래 성장 동력을 반영한 결과입니다. 특히 선행 P/E 8배와 과거 10년 이상 꾸준히 증액된 배당 지급 정책은 이 기업이 안정적인 현금 흐름을 창출하고 있음을 시사합니다. 2026년 1분기 실적에서 매출 $14.45억 달러와 EPS $0.75를 기록하며 전년 대비 5.4%의 매출 성장을 보인 점은 기업의 사업 안정성을 입증합니다. 이는 시장의 변동성에도 불구하고 꾸준한 이익 창출 능력을 보여줍니다.

본문 2: 성장 동력과 해소된 리스크

Pfizer의 장기적인 성장 전망은 핵심 특허 문제 해결과 혁신적인 제품 포트폴리오 확장에 달려 있습니다. 가장 큰 리스크였던 특허 만료 우려는 Vyndamax 특허가 2031년 6월까지 미국 독점권을 연장함으로써 상당 부분 해소되었습니다. 이는 향후 수년간 안정적인 독점적 시장 지위를 보장하여 예측 가능한 수익을 확보하게 합니다. 또한, 신규 제품의 성공적인 시장 침투는 강력한 성장 동력으로 작용하고 있습니다. Q1 2026에 출시 및 인수된 제품들은 운영적으로 22% 성장했으며, 이는 Padcev가 39%, Nurtec ODT가 41%, Abrysvo가 37% 성장한 수치로 구체화됩니다. 이러한 운영 성과는 R&D 투자와 파이프라인의 성공적인 관리 능력을 반영합니다.

본문 3: 시장 전망과 장기적 관점

Pfizer는 향후 2026년에 약 20개의 주요 연구 시작을 계획하고 있어, 지속적인 파이프라인 확장을 통해 미래 성장 잠재력을 유지할 것으로 보입니다. 이러한 연구 결과들이 성공적으로 상업화된다면, 이는 현재의 안정적인 캐시 플로우를 넘어 새로운 성장 사이클을 열어줄 수 있습니다. 변동성이 높은 시장 환경에서는 이러한 장기적인 파이프라인 투자와 확고한 현금 흐름이 투자자들에게 안정적인 포트폴리오를 구축하는 데 중요한 기준이 될 것입니다. 투자자들은 단기적인 시장 심리보다는 기업이 확보한 지적재산권과 미래 연구 결과에 초점을 맞추어 장기적인 관점에서 접근할 필요가 있습니다.

결론

결론적으로, Pfizer는 낮은 주가 수준에도 불구하고 강력한 특허 기반, 안정적인 배당 정책, 그리고 성공적인 제품 포트폴리오 확장을 통해 변동성 시장에서도 견고한 가치를 제공합니다. 투자자들은 단기적인 시장 움직임에 흔들리지 않고, 기업의 장기적인 연구 파이프라인과 현금 흐름의 지속 가능성에 주목하여 접근하는 것이 합리적일 것입니다. 향후 2026년의 임상 결과와 특허 만료 시점의 변화를 주요 관찰 포인트로 삼아야 할 것입니다.

---

원문 링크: https://247wallst.com/investing/2026/06/30/3-dirt-cheap-stocks-under-45-built-to-outperform-in-a-volatile-market/?.tsrc=rss

3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows, defensive betas, and dividend yields that make Treasury bills look pedestrian. For retail investors scanning headlines and watching their screens flicker red and green, these are the kinds of stocks worth pulling up a chair for.

With that in mind, here are three stocks trading under $45 that combine cheap valuations, durable income, and entrenched competitive moats heading into a choppier market.

Pfizer ( NYSE:PFE | PFE Price Prediction ) is the global pharmaceutical giant behind blockbusters across oncology, vaccines, primary care, and specialty medicines. At a recent $24.29, well under the $45 ceiling, the stock sits roughly mid-range of its 52-week band of $21.97 to $28.28, giving income-focused buyers an accessible entry into a mega-cap dividend payer.

The fundamentals make the case. Pfizer trades at a trailing P/E of 19 and a forward P/E of 8, with a dividend yield of 7.27% backed by a quarterly payout of $0.43 that has been raised every year for more than a decade. Wall Street’s average price target of $29.15 implies meaningful upside from current levels, with 11 buy or strong buy ratings against 15 holds and three sell-side bears. Q1 2026 results showed revenue of $14.45 billion, up 5.4% year over year, and adjusted EPS of $0.75, marking a fifth consecutive earnings beat.

The bull case rests on three pillars. First, the Vyndamax patent settlement extends U.S. exclusivity to June 2031, defusing the loudest patent cliff fears. Second, launched and acquired products grew 22% operationally in Q1, led by Padcev (+39%), Nurtec ODT (+41%), and Abrysvo (+37%). Third, CEO Albert Bourla pointed to roughly 20 pivotal study starts planned for 2026, including 10 obesity assets from the Metsera acquisition, saying the company is “particularly encouraged by what we’re seeing in oncology and obesity.”

The risk worth respecting is COVID-related revenue erosion, with Comirnaty down 59% and Paxlovid off 62%, plus a $1.5 billion loss-of-exclusivity headwind baked into 2026. Even Jim Cramer recently quipped on Mad Money that with Pfizer, “you’re just buying on that dividend yield.” For value and income investors, that may be exactly the point.

AT&T ( NYSE:T ) is the converged fiber and 5G wireless operator quietly executing one of the cleaner turnaround stories in large-cap telecom. Shares recently traded at $22.72, down 6.5% year to date, which has compressed the valuation to a level rarely seen in dominant U.S. infrastructure plays.

On the numbers, AT&T trades at a trailing P/E of 8 and a forward P/E of 10, with a dividend yield of 4.95% on a $0.2775 quarterly payout that has held steady since 2022. Analysts carry an average price target of $30.25 with 15 buy or strong buy ratings, 10 holds, and zero sell ratings. Q1 2026 brought revenue of $31.51 billion (+2.9% YoY) and adjusted EPS of $0.57, up 11.8% YoY, including the best Q1 ever for Advanced Connectivity internet net adds at 584,000.

The bull case is operational momentum colliding with capital returns. CEO John Stankey called out the “best first quarter ever for Advanced Connectivity internet customer net additions.” The closed Lumen Mass Markets fiber acquisition on February 2, 2026 pushed reach to 37 million-plus fiber locations, with a target of 60 million by 2030. Management reiterated free cash flow of $18 billion-plus in 2026, $19 billion-plus in 2027, and $21 billion-plus in 2028, and committed to $45 billion-plus in shareholder returns from 2026 through 2028, including roughly $8 billion in buybacks this year.

The risk: leverage. Net debt-to-EBITDA sits at 2.71x and rises toward 3.2x post-EchoStar and Lumen, and legacy wireline revenue is still declining 20%+. Reddit sentiment recently flipped, with r/wallstreetbets discussion turning bearish at scores of 33 to 38 on June 26-27 after running bullish earlier in the month on a congressional trade signal flagged on r/stockmarket. For investors who can stomach the leverage, the fiber flywheel and capital returns make the math interesting.

Kinder Morgan ( NYSE:KMI ) operates one of the largest natural gas pipeline, products pipeline, terminal, and CO2 networks in North America. Shares recently changed hands at $33.19, up 25.37% year to date and 143.8% over the past five years, but still comfortably under the $45 ceiling and within reach of retail-sized positions.

The setup is rare in midstream: real growth tied to secular demand. KMI trades at a trailing P/E of 22 and a forward P/E of 24, with a dividend yield of 3.56% on a $1.19 annualized payout (+2% YoY). Q1 2026 revenue rose to $4.83 billion (+13.5% YoY), adjusted EPS came in at $0.48 versus the $0.39 estimate, a 22.11% beat, and adjusted EBITDA expanded 18% to $2.54 billion. Wall Street’s average price target of $35.33 and 11 buy ratings to 12 holds and zero sells reflect the durability of the cash flow.

The bull case is direct exposure to two of the most-watched demand curves on the planet: LNG exports and U.S. data center power. Management noted long-term contracts to move 8 Bcf/d to LNG facilities today, growing to 12 Bcf/d by end of 2028, with roughly 70% of future data center power demand sitting in KMI-served states. The project backlog stands at $10.1 billion, with about 92% in natural gas, and Moody’s recently upgraded KMI to Baa1, putting all three agencies at BBB+. CEO Kim Dang attributed Q1 to “record-setting performance in our Natural Gas Pipelines business segment.”

The risk worth tracking is commodity and policy exposure: refined products volumes fell 2% and crude/condensate dropped 12%, and tariff or permitting timing can move the needle on the backlog. But with leverage at a manageable 3.6x net debt-to-EBITDA and natural gas demand projected to grow 17% through 2030, KMI looks like the cleanest pure-play infrastructure beneficiary on the list.

A share price under $45 does not, on its own, make a stock cheap or safe. What earns these three names a spot on a watch list right now is the combination of betas well below 1.0, durable dividend streams, and entrenched moats that historically hold up when the broader market gets choppy. Before adding any of them to a portfolio, readers should weigh their own time horizon, income needs, and tolerance for sector-specific risk, and do their own research on how each business fits the rest of their holdings.

Contact [email protected] for any questions or corrections.

Source: https://247wallst.com/investing/2026/06/30/3-dirt-cheap-stocks-under-45-built-to-outperform-in-a-volatile-market/?.tsrc=rss